Preventive Pharmacologic Treatments for Episodic Migraine in Adults
- 17 April 2013
- journal article
- review article
- Published by Springer Nature in Journal of General Internal Medicine
- Vol. 28 (9) , 1225-1237
Abstract
Systematic review of preventive pharmacologic treatments for community-dwelling adults with episodic migraine. Electronic databases through May 20, 2012. English-language randomized controlled trials (RCTs) of preventive drugs compared to placebo or active treatments examining rates of ≥50 % reduction in monthly migraine frequency or improvement in quality of life. We assessed risk of bias and strength of evidence and conducted random effects meta-analyses of absolute risk differences and Bayesian network meta-analysis. Of 5,244 retrieved references, 215 publications of RCTs provided mostly low-strength evidence because of the risk of bias and imprecision. RCTs examined 59 drugs from 14 drug classes. All approved drugs, including topiramate (9 RCTs), divalproex (3 RCTs), timolol (3 RCTs), and propranolol (4 RCTs); off-label beta blockers metoprolol (4 RCTs), atenolol (1 RCT), nadolol (1 RCT), and acebutolol (1 RCT); angiotensin-converting enzyme inhibitors captopril (1 RCT) and lisinopril (1 RCT); and angiotensin II receptor blocker candesartan (1 RCT), outperformed placebo in reducing monthly migraine frequency by ≥50 % in 200–400 patients per 1,000 treated. Adverse effects leading to treatment discontinuation (68 RCTs) were greater with topiramate, off-label antiepileptics, and antidepressants than with placebo. Limited direct evidence as well as frequentist and exploratory network Bayesian meta-analysis showed no statistically significant differences in benefits between approved drugs. Off-label angiotensin-inhibiting drugs and beta-blockers were most effective and tolerable for episodic migraine prevention. We did not quantify reporting bias or contact principal investigators regarding unpublished trials. Approved drugs prevented episodic migraine frequency by ≥50 % with no statistically significant difference between them. Exploratory network meta-analysis suggested that off-label angiotensin-inhibiting drugs and beta-blockers had favorable benefit-to-harm ratios. Evidence is lacking for long-term effects of drug treatments (i.e., trials of more than 3 months duration), especially for quality of life.Keywords
This publication has 139 references indexed in Scilit:
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- Frequencies of genetic polymorphisms related to triptans metabolism in chronic migraineThe Journal of Headache and Pain, 2010
- Meta-Analyst: software for meta-analysis of binary, continuous and diagnostic dataBMC Medical Research Methodology, 2009
- EFNS guideline on the drug treatment of migraine – revised report of an EFNS task forceEuropean Journal of Neurology, 2009
- The Impact of Migraine and the Effect of Migraine Treatment on Workplace Productivity in the United States and Suggestions for Future ResearchMayo Clinic Proceedings, 2009
- ACE D/I polymorphism, migraine, and cardiovascular disease in womenNeurology, 2009
- Why add anything to nothing? The arcsine difference as a measure of treatment effect in meta‐analysis with zero cellsStatistics in Medicine, 2008
- The impact of migraine prevention on daily activities: a longitudinal and responder analysis from three topiramate placebo-controlled clinical trialsHealth and Quality of Life Outcomes, 2007
- What to add to nothing? Use and avoidance of continuity corrections in meta‐analysis of sparse dataStatistics in Medicine, 2004
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986